Silicon Investor - VERISANTE TECHNOLOGY

[croman] Another article: wallstreetsectorselector.com

croman — 12/21/2013 6:59:02 PM

[dalroi] Waste of money imo They just need to demostrate their product sells

dalroi — 9/14/2013 10:16:38 AM

[andre dallaire] Short Form Prospectus Verisante Technology, Inc. Files Preliminary Short Form...

andre dallaire — 9/13/2013 5:22:09 PM

Short Form Prospectus

Verisante Technology, Inc. Files Preliminary Short Form Base Shelf Prospectus
September 20, 2013 at 7:23 pm
VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has filed a preliminary short form base shelf prospectus ("Prospectus") with the securities regulatory authorities in the provinces British Columbia, Ontario and Alberta.

Under the Prospectus, Verisante may offer and issue from time to time any combination of common shares, warrants to purchase common shares and units (collectively, the "Securities") up to an aggregate offering of $10,000,000 during the 25-month period that the Prospectus, including any amendments thereto, remains effective. Securities may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of sale and set forth in an accompanying prospectus supplement (a "Prospectus Supplement").

The Company has engaged Jordan Capital Markets, Inc. as agent for an initial offering of up to $2.5 million. Verisante will file the details of the engagement and offering in a Prospectus Supplement after the Company files the final short form base shelf Prospectus.

The net proceeds to Verisante from the sale of Securities and the proposed use of those proceeds will be set forth in the applicable Prospectus Supplement. The principal business objective to be achieved with the proceeds is to further develop and the Company’s product offerings, including Aura™, a device for the detection of all major forms of skin cancer, finance manufacturing of Aura™ devices, to pursue regulatory approval in the United States for Aura™, for ongoing additional product development of other technologies, including multispectral imaging, rapid Raman systems for endoscopic applications, and fluorescence and reflectance imaging systems, and to cover general and administrative costs and other general corporate purposes for the next 12 months.

The Company also announced today that it has retained Kilmer Lucas Inc. (“Kilmer”) to help increase investor awareness throughout North America.

The agreement with Kilmer is for a period of 12 months. Under the terms of the agreement, the Company will pay a consulting fee to Kilmer of $6,500 per month plus approved expenses incurred on behalf of the Company

Read more at http://www.stockhouse.com/companies/bullboard/v.vrs/verisante-technology,-inc?postid=21739515#uw2Te698ekw3xxmW.99

[andre dallaire] Great Move - Hired Kilmer Lucas to advance promotion and awareness to investors....

andre dallaire — 9/13/2013 4:38:12 PM

Great Move - Hired Kilmer Lucas to advance promotion and awareness to investors. The following is link to company website kilmerlucas.com

[andre dallaire] MSI system?? stockwatch.com

andre dallaire — 9/10/2013 1:40:08 PM

[andre dallaire] the life science report: t.co

andre dallaire — 9/5/2013 2:34:02 PM

[croman] sunnewsnetwork.ca! [graphic] JONATHAN SHER | QMI AGENCY LONDON, Ont. -- A new...

croman — 8/23/2013 9:21:38 AM

sunnewsnetwork.ca!

JONATHAN SHER | QMI AGENCY

LONDON, Ont. -- A new laser tool that finds potential skin cancers in seconds may get more widespread use in Ontario."We would absolutely welcome an application," Health Minister Deb Matthews said this week after QMI Agency reported how the promising laser, developed in British Columbia, was in use in only two Ontario clinics.

"Innovation is really driving our health-care system," she said.

The company behind the laser, Verisante, plans to taker her up on her offer.

"This could be very good," CEO Thomas Braun said.

Braun will encourage Ottawa neurologist Dr. Jennifer Beeker to apply for funding to buy the $65,000 machine for her pigmented lesion clinic at Ottawa Hospital.

He also plans to try to get Ontario to cover the costs of the scans themselves -- now, patients pay themselves, $75 for a single lesion or $200 for up to 15 at Medpoint in London, one of only six clinics in Canada to have one of the machines.

Those who don't access the laser often wait months to be seen by a dermatologist, with the delay in London as long as nine months.

The laser that spots chemical markers of cancer was funded partly with Canadian tax dollars and subjected to a study in British Columbia. The scanning device was created by the B.C. Cancer Agency and the University of British Columbia.

It has been tested and refined on about 1,000 lesions at the Skin Care Centre at Vancouver General Hospital.

While doctors who examine moles often miss the most serious skin cancer, melanoma, the Verisante laser, called the Aura, can detect up to 99%, Braun said.

Even board-trained dermatologists miss skin cancers far more than an Aura scan, Braun said.

The Verisante Aura captured the spotlight in 2011 when Popular Science magazine named it a top technology innovation and unlike other devices, its use is not limited to melanoma.

The Aura is also used to detect more common skin cancers and is being adapted to look for lung cancer, too -- the laser can be attached to a narrow tube that can be lowered into the lungs.

[Mark Bartlett] We need sales numbers.

Mark Bartlett — 8/19/2013 10:39:39 PM

[andre dallaire] bo-medical.com

andre dallaire — 8/19/2013 3:02:30 PM

[Mark Bartlett] Terry, Exactly! - Mark

Mark Bartlett — 8/7/2013 4:00:50 PM

[Terry Maloney] Verisante Technology, Inc. Announces Study on Nasopharnygeal Cancer in China fin...

Terry Maloney — 8/7/2013 10:20:49 AM

Verisante Technology, Inc. Announces Study on Nasopharnygeal Cancer in China
finance.yahoo.com

Also updates on lung, colon cancer studies ... but what's really needed is some news on Aura sales.

[andre dallaire] a new video {^youtubevideo|(width)560|(height)340|(rel)True|(url)http://www.yout...

andre dallaire — 7/29/2013 3:49:32 PM

a new video
{^youtubevideo|(width)560|(height)340|(rel)True|(url)http://www.youtube.com/watch?v=tVwzUljEPmM|(fs)True|(loop)False|(autoplay)False^}

[andre dallaire] exhibits in Germany: Verisante Technology, Inc. Exhibits at the World Congress o...

andre dallaire — 7/17/2013 3:20:01 PM

exhibits in Germany:
Verisante Technology, Inc. Exhibits at the World Congress of Melanoma
July 17, 2013 at 11:00 am
VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF,) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today it is exhibiting at the 8th World Congress of Melanoma in Hamburg, Germany on July 17-20.

Laserwelt, the Company’s exclusive distributor for Verisante Aura™ in Germany, Austria and Liechtenstein, will be assisting Verisante to exhibit Aura™ at our booth (No. 18A) at the Congress. Dr. Jason Rivers, a member of the Company’s Clinical Advisory Board, will also be chairing a panel discussion at the Congress entitled “Melanocytic nevi: observation or excision,” and will give a presentation entitled “Advanced diagnostic devices: do they help in the distinction between those lesions that warrant observation or excision.”

Dr. Jason Rivers is a Clinical Professor of Dermatology at the University of British Columbia, and served for seven years as national director of the Canadian Dermatology Association's Sun Awareness Program. His current practice includes cutaneous oncology, general dermatology, laser, and cosmetic dermatology. He has participated in clinical research for more than 20 years and has published more than 130 articles.

“We are excited for the opportunity to be in Hamburg to raise awareness among key opinion leaders by communicating the benefits of using a tool such as Aura™, a rapid Raman spectroscopy system, to assist in diagnosing skin cancer,” said Thomas Braun, President & CEO. “Germany is one of the largest markets in Europe for dermatological and skin care devices. Given the incidence rate of skin cancers here is approximately 20 per cent higher than the rest of Europe, we expect Germany to be an important market for Aura™.”

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma, basal cell carcinoma, and/or actinic keratosis when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

About the World Congress of Melanoma

The World Congress of Melanoma was first held in 1985 in Venice and every four years since then has attracted the international melanoma community of researchers and clinicians.

The Congress covers the entire field of melanoma and other cutaneous malignancies. Epidemiology, prevention and early detection of skin cancer shall be evaluated as methods to reverse the current trend of increasing incidences. New diagnostic devices and optical approaches that have improved the diagnostic sensitivity and specificity of detection shall also be discussed extensively.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Email: info@verisante.com
Website: www.verisante.com
Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

[andre dallaire] New tool in London: t.co

andre dallaire — 6/28/2013 1:21:11 PM

[andre dallaire] CEO update decision plus today gourou.tv

andre dallaire — 6/11/2013 5:21:03 PM

[Mark Bartlett] Let's hope we see some sales from there. - M

Mark Bartlett — 6/7/2013 3:05:44 PM

[andre dallaire] News: stockwatch.com

andre dallaire — 6/7/2013 1:41:50 PM

[Terry Maloney] Yep, now we want to see those distributors selling some themselves.

Terry Maloney — 6/4/2013 3:54:26 PM

[Mark Bartlett] Terry, Yes --saw that ... nice to see some $ coming in ... now hopefully they c...

Mark Bartlett — 6/4/2013 3:31:43 PM

Terry,

Yes --saw that ... nice to see some $ coming in ... now hopefully they can ramp it up.

Mark

[Terry Maloney] Sounds like they've sold 4 or 5 Auras to their distributors ... finance.yahoo.c...

Terry Maloney — 6/4/2013 1:40:11 PM

Sounds like they've sold 4 or 5 Auras to their distributors ...

finance.yahoo.com

[andre dallaire] core Platform it's greatly needed...and would be nice to see some more attenti...

andre dallaire — 5/30/2013 11:21:26 AM

core Platform
it's greatly needed...and would be nice to see some more attention on this device as the studies are progressed.

from the recent sedar doc summary:

"There are currently independent studies underway at Vancouver General Hospital (“VGH”) using the Core™ for the detection of lung and colon cancers.

These independent studies are 100% funded by both government granting agencies and NGOs and are being conducted by the BC Cancer Agency and Vancouver General Hospital.

The Corporation anticipates that after Aura™, our second product to market will be the Core™ for lung cancer detection.

In November 2012, the Corporation announced intermediate results from the BC Cancer Agency lung
cancer detection clinical study at VGH which builds on the initial success of the pilot study for lung
cancer detection. The pilot study was able to obtain clear in-vivo Raman spectra in one second using the
Core™ technology, and pre-neoplastic lesions were detected with a sensitivity of 96 per cent and a
specificity of 91 per cent. The current study found that the sensitivity and specificity of the new
generation system remain similarly high with the larger sample cohort with an increase in specificity and
only a slight reduction in sensitivity."

Is it needed? - here's a headline today from Canada:
leaderpost.com

Lung cancer most lethal

BY IRYN TUSHABE, LEADER-POSTMAY 30, 2013

According to the 2013 Canadian Cancer Statistics publication, lung cancer remains the leading cause of cancer deaths in Saskatchewan.

Released Wednesday, the report projected 580 people will die of lung cancer in 2013, 300 of those being men.

Donna Pasiechnik, the Canadian Cancer Society Saskatchewan's media relations and tobacco control manager, said controlling tobacco use in the province is pertinent to reducing the occurrence of cancers, especially lung cancer.

"Thirty per cent of all cancer deaths are associated with tobacco use. We know that if we can bring down smoking rates, we are going to bring down the number of cancers, lung cancer being one of those," said Pasiechnik.

According to Pasiechnik, the lung cancer death rate for men has dropped over the past 20 years, but the women's rate has stabilized.

"And that's because women started smoking later than men, so women's smoking rates peaked later than men. As well, men quit earlier and so now we are seeing their death rates drop," she said.

Saskatchewan has the highest youth smoking rate in Canada.

The report projects 2,300 - 1,200 men and 1,100 women - cancer deaths will occur this year in Saskatchewan, an improvement over last year's 2,400.

An estimated 5,300 Saskatchewan residents will be diagnosed with cancer this year.

Pasiechnik said the province has made great strides in cancer treatment.

"We are diagnosing cancers earlier, we are coming up with better treatment options and as a result, death rates are falling and survival rates are improving. Incidents continue to go up though but that's because our population is aging," she said.

Pasiechnik added that the province has put a lot of effort in screening programs for some of the cancers with the highest death rates, including one for colorectal cancer that is now available provincewide.

"Given the death rates associated with colorectal cancer, that's a positive step because polyps will be caught early and removed to prevent colorectal cancer from developing," said Pasiechnik.

According to the report, 410 men will be diagnosed with colorectal cancer this year, putting it at No. 2 after prostate and lung cancers, which will be diagnosed in 650 and 360 men, respectively.

For women in Saskatchewan, colorectal cancer comes third at 330 after breast and lung cancers at 690 and 330, respectively.

Nationwide, liver cancer has seen a three-fold increase in incidents among men and a two-fold increase in incidents among women since 2007. "That's a big concern because the survival rate for liver cancer is very poor - just 20 per cent after five years," said Pasiechnik.

According to Pasiechnik, the primary risk factors for liver cancer are hepatitis B and hepatitis C infections.

Other predisposing factors for liver cancer include heavy alcohol use, unhealthy body weight, smoking and diabetes.

In Saskatchewan this year, there will be 25 new liver cancer cases and five deaths due to liver cancer among men.

Liver cancer numbers for women are unknown this year. The last known liver cancer statistics for women are from 2007. That year, there were 14 new cases and 19 deaths due to liver cancer among women.

Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?p=0&m=32621399&l=0&r=0&s=VRS&t=LIST#Tii7fdMHj1TJxtei.99

[andre dallaire] news: stockwatch.com

andre dallaire — 5/22/2013 4:31:50 PM

[andre dallaire] Video on CHCH: chch.com

andre dallaire — 5/16/2013 11:39:01 AM

[dalroi] Seems they are disparate for cash New terms on the pipe :-(

dalroi — 5/10/2013 4:19:27 PM

[andre dallaire] News: stockwatch.com

andre dallaire — 5/10/2013 2:52:32 PM

[Mark Bartlett] There is going to be a PR shortly -- likely early next week .

Mark Bartlett — 5/10/2013 8:36:47 AM

[andre dallaire] nothing to add I am long for at least 2 to 3 years.

andre dallaire — 5/9/2013 10:08:23 PM

[dalroi] ok i'm now reading all the positive spins for over a year but bottom line is ...

dalroi — 5/8/2013 4:36:55 PM

ok

i'm now reading all the positive spins for over a year

but bottom line is

how much device did they actualy sold

we dont have one in our hospital :-(

this realy reminds me of that dialysis co which had superior home dialysis machines :-(

take care

[andre dallaire] Photonics.com article Prism Winner Nabs Edison Award VANCOUVER, British Colu...

andre dallaire — 5/8/2013 2:14:05 PM

Photonics.com article

Prism Winner Nabs Edison Award
VANCOUVER, British Columbia, Canada, May 8, 2013 — Skin cancer detector maker Verisante Technology Inc. received a bronze Edison Award in the Diagnostic/Analytic category for its noninvasive Aura device. The award was presented last month in Chicago.

In February, the Aura was selected as a 2013 Prism Award for photonics innovation winner by Photonics Media and SPIE in the Life Sciences and Biophotonics category (See: Prism Awards Honor Innovations in Photonics). The Aura won, in part, because it allows Raman-based disease detection to move into the doctor’s office for the first time, and, unlike other optical skin cancer detectors, it doesn’t use visual characteristics to assess lesions but instead images the biochemical changes in the skin (based on molecular vibrations) using a near-infrared (785 nm) laser. Click here for a video about the Aura's Prism Award win.

The Edison Awards, named after Thomas Alva Edison, are conducted by Edison Universe. Their purpose is to inspire creative minds to remain at the forefront of innovation, creativity and ingenuity in the global economy. The 2013 nominees were judged by a panel of more than 3000 leading business executives, including past winners, academics and leaders in product development, design, engineering, science and medicine, the organization said.

Aura's clinical study results, published last year in Cancer Research, showed that the device provides a significant advancement over current clinical diagnosis, Verisante said, with a 99 percent success rate in finding skin cancer and the potential to reduce unnecessary biopsies by 50 to 100 percent.

For more information, visit: www.edisonawards.com or www.verisante.com

http://www.photonics.com/Article.aspx?AID=53825

Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?p=0&m=32544901&l=0&r=0&s=VRS&t=LIST#5wQyAmtyWWFTuD3X.99

[andre dallaire] some perspective: marketwire.com

andre dallaire — 5/7/2013 12:47:52 PM

[andre dallaire] a great video t.co

andre dallaire — 5/4/2013 10:15:35 AM

[andre dallaire] Edison awards: verisante.com

andre dallaire — 4/26/2013 10:36:34 AM

[andre dallaire] video of prism awards winner::http://www.photonics.com/VideoGallery.aspx?channel...

andre dallaire — 4/18/2013 9:06:04 PM

video of prism awards winner::http://www.photonics.com/VideoGallery.aspx?channelId=138c93e50d80470ea098ddef41d83013&channelListId=4c2495b268874aa8b6980e48868f8a6c&mediaId=cdaa5d4da35643c2b76904d31f770331

[andre dallaire] News: stockwatch.com

andre dallaire — 4/16/2013 3:49:15 PM

[Mark Bartlett] Andre, No I don't -- I do not even know who that is. But I have VRS as a long-...

Mark Bartlett — 4/7/2013 5:07:50 PM

Andre,

No I don't -- I do not even know who that is.

But I have VRS as a long-term hold. I like their technology and I think they are a prime takeover target as soon as they get a little more penetration with their aura and make additional progress with their core technology.

- M

[andre dallaire] Mark do you follow v.dan, I think we have the same portfolio!!!

andre dallaire — 4/7/2013 4:00:19 PM

[Mark Bartlett] Cool!

Mark Bartlett — 4/7/2013 3:32:21 PM

[andre dallaire] facebook.com first clinic in Ontario

andre dallaire — 4/7/2013 2:59:52 PM

[andre dallaire] facebook.com next stop Zurich

andre dallaire — 4/7/2013 2:55:02 PM

[andre dallaire] New Clarion website for Verisante clarionmedical.com

andre dallaire — 3/27/2013 4:17:57 PM

[andre dallaire] FB update Oh Canada! Aura has arrived at three Canadian Clinics: Barry Lycka |...

andre dallaire — 3/26/2013 5:10:58 PM

FB update
Oh Canada! Aura has arrived at three Canadian Clinics: Barry Lycka | Your Cosmetic Doctor | Cosmetic Dermatologist, Institute for Skin Advancement, and Institute of Cosmetic & Laser Surgery.

[croman] Great interview,,,, youtube.com

croman — 3/16/2013 6:55:13 PM

[andre dallaire] from electricsocket (stockhouse) Zacks.s report today VRSEF: Meaningful Progres...

andre dallaire — 2/28/2013 4:38:38 PM

from electricsocket (stockhouse) Zacks.s report today

VRSEF: Meaningful Progress on Several Fronts

By Brian Marckx, CFA

Verisante (OTC Markets: VRSEF)/( V.VRS) continues to make meaningful progress on several fronts including commercialization of Aura, continued product development, regulatory matters, financing, and product and market awareness initiatives. Below is a quick snapshot of some of these activities over the last few months.

VRSEF Raising $4MM - $10MM

This morning (2/28/2013) Verisante announced that through two separate (one U.S., one ex-U.S.) private placements of common stock with warrants that they expect to raise between $4 million and $10 million. Verisante expects both transactions to close within the next two months.

Each offering will consist of minimum of 4 million and maximum of 10 million shares offered at $0.50/share with 100% warrant coverage. Warrants are exercisable at $0.70 (currently out of the money) with an initial term of 24 months. Verisante has the right to call in the expiration dates of the warrants to within ~30 days of the following events; 50% of warrants' if Verisante's volume weighted trading price reaches $1.00 or greater for 10 consecutive days, 100% of warrants if Verisante's volume weighted trading price reaches $1.25 or greater for 10 consecutive days.

Verisante exited Q3 (9/30/2012) with $2.8 million in cash and equivalents and has been burning (including capitalized R&D) roughly $1.3 million per quarter. This cash raise will provide significant operating capital and should help catalyze the ongoing roll-out of Aura and help to fund the U.S. regulatory program.

Distribution Further Beefed Up

On the heels of the ex-U.S. launch of Aura Verisante has significantly expanded their distribution. Over the last two months Verisante has penned agreements with several distributors covering large swaths of Europe including Germany, Switzerland, and Austria. Laserwelt has a substantial footprint throughout Germany, Austria and Lichtenstein and is a top distributor of medical devices. Germany, in particular, is expected to be an important territory for Verisante's Aura as it is the only country with a national skin cancer screening program and one of the largest markets for medical devices in general.

The other recently announced distribution agreements are with Pacifica Handels AG covering Switzerland and an expanded agreement with BO-Pharma which now also covers the Nordic countries of Norway, Denmark, Finland and Iceland in addition to the initial agreement which was for the Benelux region (Belgium, Netherlands, Luxembourg). And as a reminder, Verisante had previously announced a distribution agreement with Clarion Medical Technologies for the Canadian market.

Initial Sales Commenced

In late January Verisante announced that they received their first orders for Aura from their distributors in Canada and Europe. Manufacturing was up and running and shipping was expected to begin in the following weeks. This timeline continues to be largely commensurate with our earlier expectations.

Aura Continues To Rack Up Awards

Verisante's trophy case continues to fill up with the latest award coming in early February when Aura won the 2013 Prism Award in the Life Sciences and Biophotonics category. The award was presented to VRSEF management during the annual SPIE Photonics West conference which attracts over 1,500 companies and 20,000 attendees and which is billed as the world's largest and most influential photonics and optics event. The award recognized Aura as the best new photonics product on the market and beat out entries from throughout the world including a microscope objective from imaging giant Olympus and an ultrafast laser from Femtolasers, both of which were finalists for the award.

Just days after the SPIE event Aura was named a 2013 finalist for an Edison Award under the Science/Medical, Diagnostic/Analytical Systems category. Per the Edison Awards website describing the awards,

"The Edison Awards™ are among the most prestigious accolades honoring excellence in new product and service development, marketing, human-centered design and innovation. Unique to the world of award programs, the Edison Awards™ are focused on the innovators as much as the innovations. Award winners represent "game changing" products, services and excellence and leadership in innovation around four criteria: Concept, Value, Delivery and Impact. An Edison Award represents significant value to the award winner and to the cause of innovation."

Verisante and Aura again appear to be in good company as a finalist. The other three finalists in their category are; 3M Molecular Detection System by 3M, AccuVein AV400 by AccuVein Inc, and 3-D Motion Capture System by Dynamic Athletic Research Institute.

As a reminder Verisante and their cancer detection products and technology have already racked up a number of high profile accolades over the recent past including Popular Science's Best of What's New Award for 2011, being named as a top cancer breakthrough of 2011 by the Canadian Cancer Society and the company being named as the top ranking technology and life sciences company on the TSX Venture 50.

Please visit SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning.

Read the Full Research Report on V.VRS

Read the Full Research Report on VRSEF

Zacks Investment Research

Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?p=0&m=32250244&l=0&r=0&s=VRS&t=LIST#CeYklf1oFRYvzz6M.99

[andre dallaire] no

andre dallaire — 2/28/2013 10:32:55 AM

[dalroi] hi any idea why they do a pipe here and not a bridge loan or a partnership with...

dalroi — 2/28/2013 5:49:55 AM

hi

any idea why they do a pipe here and not a bridge loan or a partnership with a medical manufacturer like jnj ?

[andre dallaire] Verisante arranges up to $10-million private placements Ticker Symbol: C:VRS ...

andre dallaire — 2/27/2013 4:29:11 PM

Verisante arranges up to $10-million private placements
Ticker Symbol: C:VRS Verisante arranges up to $10-million private placements Verisante Technology Inc (C:VRS)
Shares Issued 69,973,982
Last Close 2/26/2013 $0.52
Wednesday February 27 2013 - News Release

Mr. Thomas Braun reports

VERISANTE TECHNOLOGY, INC. ANNOUNCES BROKERED PRIVATE PLACEMENTS

Verisante Technology Inc. intends to complete two separate and independent brokered private placements through Raymond James Ltd. (agent for sales in Canada only) and a separate agent for sales in the United States. The private placement to be conducted by Raymond James Ltd. shall be for a minimum of 4,000,000 to a maximum of 10,000,000 units at $0.50 per unit for total gross proceeds of a minimum of $2,000,000 and a maximum of $5,000,000, and the private placement to be conducted by the Company's US Agent shall be for a minimum of 4,000,000 to a maximum of 10,000,000 units at $0.50 per unit for total gross proceeds of a minimum of $2,000,000 and a maximum of $5,000,000, (collectively, the "Offerings").

Each unit will comprise of one common share and one common share purchase warrant (the "Warrants"). Each Warrant will entitle the holder to purchase one common share at a price of $0.70 per share with an expiry date of 24 months from the closing of the Offerings.

The Warrants shall have two call provisions whereby in the event the volume weighted average trading price of Verisante's common shares on the TSX Venture Exchange (the "Exchange") is equal to or greater than $1.00 for 10 consecutive trading days, the Company will have the right to accelerate the expiry date of 50% of the total Warrants issued under the Offerings to a date that is 30 days after Verisante issues a news release announcing that it has elected to exercise this acceleration right. Under the second call provision, in the event the volume weighted average trading price of Verisante's common shares on the Exchange is equal to or greater than $1.25 for 10 consecutive trading days, the company will have the right to accelerate the expiry date of remaining 50% of the total Warrants issued under the Offerings to a date that is 30 days after Verisante issues a news release announcing that it has elected to exercise this acceleration right.

Closing of the Offerings are scheduled to occur on or before April 30, 2013 or at any other such time as the Company and each Agent may agree, subject to the approval of the Exchange, the Agents' satisfactory due diligence, and other customary conditions. The securities to be issued in connection with the Offerings will be subject to a four month statutory hold period.

The net proceeds of the Offerings will be used to fund the Company's manufacturing of Aura(TM), to pursue additional regulatory approvals of Aura(TM) in the United States and other regions, to support sales and marketing initiatives, and for working capital requirements. Commissions may be paid in connection with the Offerings consisting of 10% of the gross proceeds of the Offerings, and agent's warrants entitling the holder thereof to acquire common shares of Verisante in an amount equal to 10% of the number of units sold by the Agents, which agent's warrants shall have the same terms as the Warrants.

We seek Safe Harbor.

© 2013 Canjex Publishing Ltd.

[andre dallaire] News stockwatch.com

andre dallaire — 2/19/2013 1:41:24 PM

[stocksman55555] No pitch here just looking for the facts. More than happy to discuus the depleti...

stocksman55555 — 2/14/2013 11:44:02 PM

No pitch here just looking for the facts. More than happy to discuus the depleting cash, the huge money spent on promo, all the disinformation being spread on boards etc. I like to post facts and take my information from publicly available filings like the one that shows VRS in debt to BCCA for $308K and overdue long enough that VRS may be in default. All shareholders should be gravely concerned until this issue is answered. Then the next issue is where is the cash going to come from to keep VRS operating past April/May? It sure is not coming from sales.

[stocksman55555] Great more fluff, How about addressing the issues. No sales to speak of, debt to...

stocksman55555 — 2/13/2013 9:00:39 PM

Great more fluff, How about addressing the issues. No sales to speak of, debt to BCCA, declining cash reserves, disproportionate amount spend on promo, no R&D etc.

[croman] Verisante Named Edison Awards FinalistMarketwire - Canada VANCOUVER, BRITISH CO...

croman — 2/13/2013 10:40:17 AM

Verisante Named Edison Awards Finalist Marketwire - Canada

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 13, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that Verisante Aura(TM), a revolutionary skin cancer detection device, has been named a 2013 finalist by the internationally renowned Edison Awards(TM). The distinguished awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring creative minds to remain in the forefront of innovation, creativity and ingenuity in the global economy.

"More than we have seen at any other time previously, this year's slate of finalists demonstrate the enormous value of teamwork, experimentation, consumer focus, market awareness and game-changing success," said Frank Bonafilia, Edison Awards' executive director. "It's exciting to see companies like Verisante continuing Thomas Edison's legacy of challenging conventional thinking."

"It is an honour to be selected as an Edison Awards finalist," said Thomas Braun, President & CEO of Verisante. "Aura(TM) is a game-changing innovation that will significantly improve patient outcomes and care. It has taken some of the field's brightest minds and years of research and commitment to bring this technology to commercialization."

The ballot of nominees for the Edison Awards is judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the finalists' success in meeting the award criteria of Concept, Value, Delivery and Impact. The panel includes members of the Marketing Executives Networking Group (MENG), the American Association Advertising Agencies (4As), the Chief Marketing Officer Council (CMO), the Design Management Institute (DMI), the American Productivity & Quality Center (APQC), the American Society of Mechanical Engineers(ASME) and the Association of Technology Management & Applied Engineering (ATMAE). Also on the panel are hundreds of past Edison Award winners, marketing professionals, scientists, designers, engineers and academics.

Award winners will be announced April 25, 2013 at the Edison Awards Annual Gala, held in the Grand Ballroom at historic Navy Pier in Chicago, IL.

About the Edison Awards

The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering future innovators. The 2013 Edison Awards are sponsored by Nielsen, Discovery Communications, Science Channel, and USA Today. For more information about the Edison Awards, Edison Universe and a list of past winners, visit www.edisonawards.com.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura(TM) has been approved for sale in Canada,Europe and Australia. The Core(TM) has not yet been approved for sale.

Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and awarded a 2013 Prism Award for Innovation in Photonics. Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

Website: www.verisante.com

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

FOR FURTHER INFORMATION PLEASE CONTACT: Verisante Technology, Inc.Thomas Braun President & CEO (604) 605-0507 info@verisante.com www.verisante.comThe TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Source: Verisante Technology, Inc.